Search

Your search keyword '"Losonczy, G."' showing total 362 results

Search Constraints

Start Over You searched for: Author "Losonczy, G." Remove constraint Author: "Losonczy, G."
362 results on '"Losonczy, G."'

Search Results

101. Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.

102. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.

103. Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.

104. Low prevalence of spectacle use in the Hungarian Roma population indicates unmet health needs.

105. Right ventricular adaptation in pulmonary arterial hypertension

106. Tear Mediators NGF along with IL-13 Predict Keratoconus Progression.

107. Nivolumab-Induced Ulcerative Keratitis-A Case Report.

108. Severe hypoxaemia without dyspnoe in COVID-19 pneumonia

109. Blood eosinophils on hospital admission for COPD exacerbation do not predict the recurrence of moderate and severe relapses.

110. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

111. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.

112. Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer.

113. Circulating P-Selectin Glycoprotein Ligand 1 and P-Selectin Levels in Obstructive Sleep Apnea Patients.

114. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

115. Comprehensive coronary plaque assessment in patients with obstructive sleep apnea.

116. Association Between Serum Lipid Profile and Obstructive Respiratory Events During REM and Non-REM Sleep.

117. Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD.

118. A suitable protocol for measuring alveolar nitric oxide in asthma with differing severity to assess peripheral airways inflammation.

119. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.

120. Effects of aging on corneal parameters measured with Pentacam in healthy subjects.

121. The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study.

122. Complement system activation in obstructive sleep apnea.

123. Human CD40 ligand-expressing type 3 innate lymphoid cells induce IL-10-producing immature transitional regulatory B cells.

124. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.

125. Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease.

126. Relative anterior microphthalmos in oculodentodigital dysplasia.

127. Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients.

128. Role of lung volume and airway inflammation in obstructive sleep apnea.

129. Diurnal variation of circulating microvesicles is associated with the severity of obstructive sleep apnoea.

130. Cultivation of Human Oral Mucosal Explants on Contact Lenses.

131. Seasonal changes of lower respiratory tract infections in lung transplant recipients during the first post-transplant year: The Hungarian experience.

132. Myopia and Late-Onset Progressive Cone Dystrophy Associate to LVAVA/MVAVA Exon 3 Interchange Haplotypes of Opsin Genes on Chromosome X.

133. Airway dynamics in COPD patients by within-breath impedance tracking: effects of continuous positive airway pressure.

134. Overnight Changes in Lung Function of Obese Patients with Obstructive Sleep Apnoea.

135. Correction of irregular and induced regular corneal astigmatism with toric IOL after posterior segment surgery: a case series.

136. Circulating Clusterin and Osteopontin Levels in Asthma and Asthmatic Pregnancy.

137. Circulating periostin level in asthmatic pregnancy.

139. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.

140. Femtosecond laser-assisted keratoplasty combined with cataract extraction in a patient with keratoconus and oculocutaneous albinism.

141. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

142. Exhaled breath condensate pH decreases following oral glucose tolerance test.

143. Exhaled Breath Condensate pH in Lung Cancer, the Impact of Clinical Factors.

144. Presence of Fleischer ring and prominent corneal nerves in keratoconus relatives and normal controls.

145. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

146. Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.

147. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

148. Evening and morning exhaled volatile compound patterns are different in obstructive sleep apnoea assessed with electronic nose.

149. Ophthalmological phenotype associated with homozygous null mutation in the NEUROD1 gene.

150. Plasma VEGF levels and their relation to right ventricular function in pulmonary hypertension.

Catalog

Books, media, physical & digital resources